Clinical and Translational Core (Core C)

临床和翻译核心项目摘要 肾脏疾病使受影响的个体容易患终末期肾病（ESRD）， 心血管疾病（CVD）和过早死亡。据估计有近 3000 万美国人 慢性肾病，医疗费用巨大。识别新机制 肾脏疾病及相关并发症的发病机制亟待改善临床不良反应 结果并减轻美国医疗保健系统的财务负担。乔治·M·奥布莱恩肾脏 西北大学研究核心中心（NU-GoKIDNEY）将促进和支持研究 发现将改变肾脏疾病预防和治疗的新疗法 疾病并最终治愈。该中心将联合基础和临床研究人员开展 转化研究的重点是发现针对患有以下疾病的患者的新治疗方式 肾脏疾病。临床前模型核心和治疗药物开发催化的研究 核心将导致新疗法的发现，这些疗法将通过以下活动转化为患者： 临床和转化核心。核心领导将共同努力，协同推进 该中心的主要目标是寻找新的治疗方法来改善肾脏疾病患者的生活。的 临床和转化核心将提供一个集中的环境、必要的资源和多方面的支持。 学科专业知识，以安全、合乎道德的方式转化和瞄准临床前研究确定的发现 模型和治疗开发核心融入正确的患者群体。我们将高效连接 研究人员：（1）现有临床研究基础设施的最合适的组成部分； (2) 相关分析专家； (3) 肾病学研究中不常用方法的人才匹配，(4) 独特的数据和生物样本存储库； (5) 以社区为基础的研究参与者和领导者 生物伦理学和医学人文学科。我们的目标是：（1）加强机构优势整合 临床研究； (2) 鼓励核心内部和核心之间的跨学科合作； (3) 至 将新学科引入肾脏疾病研究领域； （四）提高调查人员的能力 通过访问数据和生物样本存储库对参与者进行表型分析； (5) 丰富经验 研究参与者通过争取生物伦理学家、研究参与者和社区提供者的参与 制定研究方案。通过利用我们强大的制度环境、现有资源和 多学科专业知识，临床和转化核心将加速临床前研究的转化 对肾脏疾病患者的健康改善有意义的发现。

PROJECT SUMMARY TO CLINICAL AND TRANSLATION CORE Kidney diseases predispose affected individuals to high rates of end stage renal disease (ESRD), cardiovascular disease (CVD) and premature death. With nearly 30 million Americans estimated to have chronic kidney disease, the healthcare costs are tremendous. Identification of novel mechanisms for the pathogenesis of kidney diseases and related complications is urgently needed to improve adverse clinical outcomes and to reduce the financial burden on the US healthcare system. The George M. O'Brien Kidney Research Core Center at Northwestern University (NU-GoKIDNEY) will promote and support research into the discovery of novel therapeutics that will transform the prevention and treatment of kidney diseases and eventually lead to cures. The Center will join basic and clinical investigators to conduct translational research focused on the discovery of novel therapeutic modalities for patients with kidney diseases. Research catalyzed by the Preclinical Models Core and the Therapeutics Development Core will lead to discoveries of novel therapies, which will be translated into patients through the activities of the Clinical and Translational Core. The Core Leaders will work together to synergistically advance the Center’s chief goal of finding new treatments that will improve the lives of patients with kidney diseases. The Clinical and Translational Core will provide a centralized environment, essential resources and multi- disciplinary expertise to safely and ethically translate and target the discoveries identified by the Preclinical Model and Therapeutics Development Cores into the right patient population. We will efficiently connect investigators with: (1) the most appropriate components of the existing clinical research infrastructure; (2) relevant analytic experts; (3) well-matched talent in methods not commonly used in nephrology research, (4) unique data and biosample repositories; and (5) community-based research study participants and leaders in bioethics and medical humanities. Our goals are: (1) to enhance the integration of institutional strengths in clinical research; (2) to encourage cross-disciplinary collaboration within and between the Cores; (3) to introduce new disciplines into the field of kidney diseases research; (4) to improve the ability of investigators to phenotype participants through access to data and biosample repositories; and (5) to enrich the experience of study participants by enlisting involvement of bioethicists, study participants and community providers in the development of research protocols. By leveraging our strong institutional environment, existing resources and multidisciplinary expertise, the Clinical and Translational Core will accelerate the translation of preclinical discoveries into meaningful health improvements for patients with kidney diseases.